This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Neoplasms  • Dermatologic Procedures  • Immunotherapy  • Immunology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Hensin Tsao, MD, PhD; Peri Millman, MD; Gerald P. Linette, MD, PhD; F. Stephen Hodi, MD; Arthur J. Sober, MD; Mark A. Goldberg, MD; Frank G. Haluska, MD, PhD

Arch Dermatol. 2002;138:799-802.

Background  Reports of vitiligo associated with metastases and rare cases of spontaneous regression of disease have fueled enthusiasm for immunologic approaches to the treatment of advanced melanoma. More recent strategies have focused on using antigen-presenting dendritic cells as vaccines.

Observations  We observed 3 cases of leukoderma associated with a novel adenovirus-mediated gp100/MART-1–transduced dendritic cell (MART indicates melanoma antigen recognized by T cells). All 3 patients had advanced metastatic melanoma. Despite the development of this leukodermic response, all patients experienced disease progression while under treatment.

Conclusion  We provide the initial evidence for effective induction of a leukodermic response with a gp100/MART-1–transduced dendritic cell vaccine.

From the Department of Dermatology (Drs Tsao and Sober), the Wellman Laboratories of Photomedicine (Dr Tsao), the Melanoma Center (Drs Tsao, Sober, and Haluska), and the Division of Oncology (Dr Haluska), Massachusetts General Hospital, and the Department of Adult Oncology, Dana Farber Cancer Institute (Dr Hodi), Boston, Mass; the Department of Pediatrics, Albert Einstein College of Medicine, New York (Bronx), NY (Dr Millman); the Department of Medicine, Washington University, St Louis, Mo (Dr Linette); and Genzyme Molecular Oncology, Framingham, Mass (Dr Goldberg). Dr Goldberg is an employee of, and owns stock in, Genzyme Corporation Pharmaceuticals, Framingham.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients
Luiten et al.
JCO 2005;23:8978-8991.
ABSTRACT | FULL TEXT  

Management of Cutaneous Melanoma
Tsao et al.
NEJM 2004;351:998-1012.
FULL TEXT